FiercePharmaAsia combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.
It's the big numbers that tend to make headlines during earnings season: Overall sales, top-selling meds, and, of course, earnings per share. Some closely watched new drugs have a moment in the sun, too. But other launches? Barely a glimpse--if any at all. Here's a roundup of the launch stats that caught our eyes.
Sanofi partner MyoKardia is getting a fresh injection of capital, garnering $46 million in its Series B as the South San Francisco-based biotech plots the next stage of its clinical journey developing new drugs for genetically defined groups of heart patients.
Sanofi beat expectations for sales and earnings this quarter. Both grew, even without an extra bounce from exchange rates. And for once, the diabetes blockbuster Lantus wasn't driving the caravan.
After departing from Sanofi last year for the CEO's chair at Synta Pharmaceuticals, Anne Whitaker is now moving on to Valeant, where she'll step into the role of EVP and group chairman.
Sanofi is again trimming its oncology pipeline, walking away from an armed-antibody cancer treatment licensed from ImmunoGen as it reshapes its approach to the field.
Alnylam's lead RNAi treatment continued to prevent nerve damage tied to a rare disease in an ongoing Phase II study, paving the path for late-stage development.
Sanofi is suing startup Diagnosia over the publication of information about side effects and drug interactions in its physician decision support software.
Sanofi has reached out to its French neighbor Innate Pharma to collaborate on armed antibody treatments, borrowing the biotech's technology to craft new treatments for cancer and inflammatory disease.
Sanofi plans to manufacture its highly anticipated dengue vaccine in a French facility built specifically for the product. But Sanofi Pasteur's vaccine operation in Swiftwater, PA, is also expanding in preparation for a launch of the vax, which may happen later this year.